title: Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation.
abstract: HTLV-1-associated acute adult T-cell leukaemia-lymphoma (ATL) is a highly aggressive malignant disorder with a median survival of 6 months or less. We describe an Afro-Caribbean female with very poor prognosis ATL who underwent chemotherapy with a 4 d infusion schedule of cyclophosphamide, doxorubicin and etoposide, followed by successful allogeneic bone marrow transplantation (BMT) from her HTLV-1-negative histocompatible sister. The patient remains in complete remission 23 months after BMT and has 100% donor haemopoiesis with no evidence of HTLV-1 infection on PCR testing. We suggest that allo-BMT can prolong disease free survival or may even be curative in HTLV patients.
authors.affiliation: University Department of Clinical Haematology, Manchester Royal Infirmary, London.
authors.forename: A
authors.initials: A
authors.lastname: Borg
authors.forename: J A
authors.initials: JA
authors.lastname: Yin
authors.forename: P R
authors.initials: PR
authors.lastname: Johnson
authors.forename: J
authors.initials: J
authors.lastname: Tosswill
authors.forename: M
authors.initials: M
authors.lastname: Saunders
authors.forename: D
authors.initials: D
authors.lastname: Morris
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006085:Graft Survival; D006801:Humans; D007262:Infusions, Intravenous; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000628:therapy*; D014184:Transplantation, Homologous
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide